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Human upcyte® hepatocytes are proliferating hepatocytes that retain many
characteristics of primary human hepatocytes. We conducted a comprehensive
evaluation of the application of second-generation upcyte® hepatocytes from
four donors for inhibition and induction assays using a selection of reference
inhibitors and inducers. CYP1A2, CYP2B6, CYP2C9, and CYP3A4 were repro-
ducibly inhibited in a concentration-dependent manner and the calculated IC50
values for each compound correctly classified them as potent inhibitors.
Upcyte® hepatocytes were responsive to prototypical CYP1A2, CYP2B6,
CYP2C9, and CYP3A4 inducers, confirming that they have functional AhR-,
CAR-, and PXR-mediated CYP regulation. A panel of 11 inducers classified as
potent, moderate or noninducers of CYP3A4 and CYP2B6 were tested. There
was a good fit of data from upcyte® hepatocytes to three different predictive
models for CYP3A4 induction, namely the Relative Induction Score (RIS),
AUCu/F2, and Cmax,u/Ind50. In addition, PXR (rifampicin) and CAR-selective
(carbamazepine and phenytoin) inducers of CYP3A4 and CYP2B6 induction,
respectively, were demonstrated. In conclusion, these data support the use of
second-generation upcyte® hepatocytes for CYP inhibition and induction
assays. Under the culture conditions used, these cells expressed CYP activities
that were equivalent to or higher than those measured in primary human hepa-
tocyte cultures, which could be inhibited or induced by prototypical CYP inhib-
itors and inducers, respectively. Moreover, they can be used to predict in vivo
CYP3A4 induction potential using three prediction models. Bulk availability of
cells from multiple donors makes upcyte® hepatocytes suitable for DDI screen-
ing, as well as more in-depth mechanistic investigations.
Abbreviations
ABT, 1-aminobenzotriazole; AhR, aryl hydrocarbon receptor; AUC, area under the
curve; CAR, constitutive androstane receptor; Cmax,u, unbound plasma concentra-
tion of the drug; CYP, cytochrome P450; DMSO, dimethyl sulfoxide; F2, concentra-
tion causing a twofold induction; HGM, hepatocyte growth medium; HPM,
high-performance medium; HTM, hepatocyte thawing medium; Ind50, concentra-
tion causing 50% maximal induction; Indmax, maximum fold induction;
KHB, Krebs henseleit buffer; PBS, phosphate-buffered saline; PD, population dou-
bling; RIS, relative induction score; TLDA, Taqman® low-density array; UGT,
UDP-glucuronosyltransferase; XMEs, xenobiotic metabolizing enzymes.
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Introduction
Drugs that inhibit xenobiotic metabolizing enzymes
(XMEs) responsible for their own metabolism or that of a
coadministered drug, decrease their metabolic clearance,
resulting in higher plasma concentrations to potentially
toxic levels. Indeed, most fatal drug–drug interactions are
due to XME inhibition (Zhou et al. 2007). In addition to
inhibition, drugs that induce XMEs are also avoided in
drug development as increased levels of XMEs increase
the metabolic clearance of drugs, which may cause the
plasma levels to drop below the therapeutic threshold.
Therefore, it is important to identify potent drug inhibi-
tors and inducers of XMEs at an early stage in drug
screening to deselect them from development or provide
labeling once they are marketed. Primary human hepato-
cytes are the standard in vitro model for evaluating the
induction potential of new drugs (Hewitt et al. 2007).
However, due to the sporadic quality and quantity of
these cells, researchers have explored alternative models
for investigating cytochrome P450 (CYP) induction.
There have been a number of cell types investigated,
including HepG2, HepaRG, and Fa2N-4 cells (Youdim
et al. 2007; Kanebratt and Andersson 2008). However,
these all represent a single donor; HepG2 cells lack suffi-
cient responsiveness to CYP3A4 inducers (Westerink and
Schoonen 2007); and Fa2N-4 cells lack constitutive
androstane receptor (CAR) expression (Hariparsad et al.
2008). Therefore, there is still a need for a predictive
hepatic model which could be used in early drug screen-
ing for metabolism and potential for DDIs.
Human upcyte® hepatocytes (www.upcyte.technolo
gies.com) are derived from primary human hepatocytes
by transducing them with proliferating genes and induce
them to undergo a finite number of cell divisions without
being immortalized or losing adult primary cell pheno-
type (e.g., adult cell markers, albumin production, XMEs
(Burkard et al. 2012)). This technology can be applied to
different cells types (e.g., microvascular endothelial cells
(Scheller et al. 2013)) and to different cell batches, so that
a range of primary cells from multiple donors can exhibit
an extended lifespan. Over 12 billion upcyte® hepatocytes
can be generated from one vial of primary human he-
patocytes thus meeting the high demand for predictive
human-based cell screening studies. The first-generation
upcyte® hepatocytes were shown to be responsive to CYP
inducers and for CYP3A4, the extent of induction in up-
cyte® hepatocytes generally reflected that in the paired
primary cells (Burkard et al. 2012). CYP1A2, CYP2B6,
and CYP3A4 were all induced by prototypical inducers at
the mRNA level; however, CYP2B6 activities were not sig-
nificantly induced by phenobarbital, suggesting that addi-
tional optimization was necessary. The upcyte®
technology was therefore modified and second-generation
upcyte® hepatocytes were developed according to Levy
et al. (2015). These cells also exhibit a differentiated phe-
notype, forming metabolically functional and polarized
cultures with functional bile canaliculi. The expression of
nuclear receptors, phase 1 and 2 enzymes, and drug trans-
porter genes was also comparable to primary human he-
patocytes. As with the first-generation upcyte®
hepatocytes, second-generation cells lack fetal markers
and express cytokeratin 8 and 18, human serum albumin
and store glycogen, and these characteristics are present
over different growth stages (Levy et al. 2015).
In order to use upcyte® hepatocytes in metabolism or
inhibition studies, they need to express high CYP activi-
ties. We describe here how the culture conditions were
optimized to favor higher CYP activities such that they
were suitable for both metabolism and CYP inhibition
studies. As a proof of principle, we investigated whether
upcyte® hepatocytes can be used in classical CYP inhibi-
tion assays using known potent CYP inhibitors. We
selected a-naphthoflavone, miconazole, and ketoconazole
as competitive inhibitors of CYP1A2, CYP2C9, and
CYP3A4, respectively (Mao et al. 2012; Moeller et al.
2013). Ticlopidine was used as an inhibitor of CYP2B6
activities (Turpeinen et al. 2004). Ticlopidine is a mecha-
nism-based inhibitor of CYP2B6 and its metabolism by
CYP2B6 (and not other CYPs) leads to the formation of
a reactive metabolite that inhibits the enzyme (Richter
et al. 2004). A second laboratory also tested upcyte®
hepatocytes to compare basal CYP activities and their
inhibition.
We have also investigated the application of second-
generation upcyte® hepatocytes for use in CYP induction
screening assays. Aryl hydrocarbon receptor (AhR)-,
CAR-, and PXR-mediated induction was measured using
prototypical inducers recommended by the FDA: omepra-
zole (AhR-mediated induction of CYP1A2), phenobarbital
(CAR-mediated induction of CYP2B6), and rifampicin
(PXR- and CAR-mediated induction of CYP2C9 and
CYP3A4) (FDA, 2012). CYP induction was monitored by
measuring CYP activities, rather than changes in mRNA
expression to ensure that the whole pathway of induction
resulting in active enzyme proteins was functional in
these cells. The in vitro–in vivo CYP3A4 induction corre-
lation has been modeled using predictions based on the
maximum fold induction (Indmax), the concentration
causing 50% maximal induction (Ind50), or the concen-
tration causing a twofold induction (the “F2”). The
Indmax and Ind50 can be related to the unbound drug
plasma concentration (Cmax,u) using the Relative Induc-
tion Score (RIS) and compared to the in vivo induction
of CYP3A4 by each drug. Data generated from CYP3A4
induction studies using upcyte® human hepatocytes were
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applied to three models recommended by PhARMA (Chu
et al. 2009) to determine whether they can mimic the
correlations already established for human hepatocytes
(Fahmi et al. 2008).
Materials and Methods
Materials
Hepatocyte growth medium (HGM), high-performance
medium (HPM), and hepatocyte thawing medium
(HTM) were all obtained from Medicyte GmbH, Heidel-
berg, Germany. Ham F12 and Williams E media, L-gluta-
mine, HEPES, sodium pyruvate, penicillin, and
streptomycin were purchased from Gibco (Paisley, UK).
Trypsin/EDTA was obtained from PAN, and phosphate-
buffered saline (PBS) with calcium or magnesium was
from GE Healthcare Life Sciences, Freiburg, Germany.
The MTS assay was a kit from Promega, Mannheim, Ger-
many (CellTiter 96® AQueous Non-Radioactive Cell). All
the inducers and inhibitors and probe substrates and their
metabolites (midazolam, 10-hydroxymidazolam, tolbuta-
mide, 4-hydroxytolbutamide, dextromethorphan, dextror-
phan, phenacetin, and O-deethyl-phenacetin) were from
Sigma–Aldrich, Seelze, Germany. The 10-hydroxymidazo-
lam glucuronide was synthesized by the Isotope Chemis-
try and Metabolites Synthesis Department of Sanofi
(Chilly-Mazarin, France). Stock solutions were prepared
using dimethyl sulfoxide (DMSO) as the solvent (Appli-
Chem GmbH, Darmstadt, Germany) for all test com-
pounds (except for phenobarbital, which was dissolved in
PBS) and were stored at 20°C for no longer than
2 months. All other chemicals were of analytical grade,
unless otherwise stated, and were of the highest purity
possible (obtained from Sigma–Aldrich, Merck GmbH or
AppliChem GmbH). All CYP assays were carried out
using collagen type I-coated 48-well plates (Corning Life
Sciences, Amsterdam, The Netherlands).
Cells and media
Second-generation upcyte® hepatocytes (Donors 10-03,
151-03, 422A-03 and 653-03) were from Medicyte GmbH,
Heidelberg, Germany. All cells used in these studies were
quality controlled and shown to lack a-fetoprotein but
expressed cytokeratin 8 and 18, human serum albumin,
and stored glycogen (measured using PAS staining). Pri-
mary human hepatocytes were from Invitrogen, North
Carolina, or from KaLy–Cell, Strasbourg, France. The cul-
ture conditions for all cells and experiments were the
same: incubation in a humidified incubator maintained at
37°C and 5% CO2 and 95% air. Upcyte
® hepatocytes
with a PD of 20–25 were used for all studies. Upcyte®
and primary human hepatocytes were thawed in HTM
and Williams Medium E (containing 0.1% BSA, 100 lg/
mL streptomycin and 100 U/mL penicillin), respectively.
The initial cell viability and density were determined
using Trypan blue exclusion or a ScepterTM Automated
Cell Counter from Millipore, Darmstadt, Germany.
Experiments conducted in Lab 1
The following methods were carried out in Lab 1, Medi-
cyte, Heidelberg, Germany.
Upcyte® hepatocyte preculture and conditioning
conditions
Two preculture durations were used: A standard precul-
ture of 3 days, with a population doubling (PD) of one,
or a longer 6- to 7-day preculture with a PD of 3.5. Stan-
dard precultures were used for testing the induction of all
four CYPs by a single concentration of inducer (as
part of the quality control of the cell batch). All other
inhibition and induction assays were conducted using a
6–7 day preculture period.
Standard preculture involved seeding the cells at
75,000 cells/cm2 HPM medium (0.5 mL/well) in collagen
type I-coated 48-well plates. The cells were cultured for
3 days without a medium change, after which time, the
medium was replaced with fresh HPM with the respective
control and inducer compounds. The cells were cultured
for a further 3 days during which time the medium was
replaced daily with HPM containing the positive control
inducers (50 lmol/L omeprazole for CYP1A2, 2 mmol/L
phenobarbital for CYP2B6 and 20 lmol/L rifampicin for
CYP2C9 and CYP3A4) or vehicle controls (0.1% PBS as
the phenobarbital solvent and 0.1% DMSO for all other
compounds).
For the longer preculture period, upcyte® hepatocytes
were seeded at 5000 cells/cm2 in collagen type I-coated
T150 flasks in HGM and precultured for up to 1 week or
until they reached 70–80% confluence. The medium was
changed every 2–3 days. The cells were then trypsinized
and reseeded into 48-well plates at 150,000 cells/cm2
(confluence) in HPM (0.5 mL per well).
Upcyte® hepatocyte inhibition assays
For inhibition assays conducted in Lab 1, after the cells
had attached (2–4 h), the medium was replaced with
either HGM or HPM containing either 0.1% or 0.5%
DMSO. The cells were cultured for a further 3 days dur-
ing which time the medium was replaced daily with the
appropriate medium. Cultures which were subsequently
used for CYP1A2 inhibition assays were treated daily for
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3 days with 100 lmol/L omeprazole to preinduce this
CYP. After this time, the cells were used for inhibition
assays. The cells were washed twice with PBS (containing
Ca2+ and Mg2+) and preincubated with 0.1 mL of an
appropriate CYP inhibitor dissolved in Krebs Henseleit
buffer (KHB). a-naphthoflavone (0.1–10 lmol/L), mico-
nazole (0.01–50 lmol/L), and ketoconazole (0.01–
20 lmol/L) were preincubated for 5 min and ticlopidine
(0.01–50 lmol/L) was preincubated for 30 min (as this is
a mechanism-based inhibitor). CYP activities were mea-
sured by adding 0.1 mL of the CYP-selective substrate in
KHB and incubating for 1 h (final concentrations were:
26 lmol/L phenacetin, 500 lmol/L bupropion, 75 lmol/
L tolbutamide, and 250 lmol/L testosterone).
Upcyte® hepatocyte induction assays
There were two types of induction assays carried out: (1)
standard induction assays in which a single concentration
of prototypical CYP inducer was tested to determine
CYP1A2, CYP2B6, CYP2C9, and CYP3A4 induction and
(2) calibration induction assays in which a range of con-
centrations of test compounds were incubated to deter-
mine their potential to induce CYP2B6 and CYP3A4
only. For both assays, after attachment of upcyte®
hepatocytes in 48-well plates, the medium was replaced
with HPM and the cells were cultured for 24 h. After this
time, the cells were treated daily for 3 days with the test
compound/prototypical inducer (required for induction
assays measuring activities, as opposed to mRNA mea-
surements, which only require 2 days).
For standard induction assays, the prototypical induc-
ers were 50 lmol/L omeprazole (CYP1A2 inducer),
1 mmol/L phenobarbital (CYP2B6 inducer), and
20 lmol/L rifampicin (CYP2C9 and CYP3A4 inducer). At
the end of the induction period, the cells were washed
with PBS and CYP activities were measured by adding
0.2 mL KHB containing final concentrations of CYP sub-
strate: 26 lmol/L phenacetin, 500 lmol/L bupropion,
75 lmol/L tolbutamide, and 250 lmol/L testosterone and
incubating for 30 min (testosterone) or 1 h (phenacetin,
bupropion, and tolbutamide). After incubation, the
supernatant was transferred to a fresh 96-well plate and
processed for HPLC analysis.
For induction assays generating dose–response curves for
CYP3A4 and CYP2B6 and subsequent calibration curves
relating to in vivo induction, the test compounds were rif-
ampicin (0.05–40 lmol/L), phenobarbital (20–2000 lmol/
L), phenytoin (1–1000 lmol/L), carbamazepine (1–
100 lmol/L), troglitazone (0.5–50 lmol/L), pioglitazone
(0.5–40 lmol/L), dexamethasone (0.1–500 lmol/L), nifed-
ipine (0.05–100 lmol/L), omeprazole (0.5–200 lmol/L),
flumazenil (0.05–100 lmol/L), and quinidine (0.1–
250 lmol/L). At the end of the induction period, the cells
were washed with PBS and 0.2 mL 250 lmol/L testosterone
in KHB was added to each well and incubated for 30 min.
The supernatant was transferred to a fresh 96-well plate
and processed for HPLC analysis. The remaining cell cul-
tures were again washed twice with PBS and then incubated
with 500 lmol/L bupropion in KHB for 1 h. The superna-
tant was transferred to a fresh 96-well plate and processed
for HPLC analysis.
Metabolite analysis by HPLC
At Medicyte, all metabolites were analyzed using UV-
HPLC. All metabolites and their respective internal stan-
dards (chlorpropamide for phenacetin, bupropion, and
tolbutamide and cortexolone for testosterone) were sepa-
rated on a SunFire C18 2.5 lm 2.1 9 20 mm column
(Waters, Munich, Germany). The mobile phases for
phenacetin metabolites were 17:1:1000 isopropanol:formic
acid:distilled water (A) and 100% methanol (B). The
peaks were detected on a UV detector set at 240 nm. The
mobile phases for bupropion and tolbutamide and their
hydroxy-metabolites were (a) 10 mmol/L KH2PO4 +5%
acetonitrile, pH 4.6 and (B) 50:50 acetonitrile:water. The
metabolites were detected on a UV detector set at
200 nm. The mobile phases for testosterone and its
metabolites were (A) 390:600:10 methanol:water: acetoni-
trile and (B) 800:180:20 methanol:water:acetonitrile. The
peaks were detected on a UV detector set at 252 nm.
Upcyte® hepatocyte culture viability and protein
content
The viability of upcyte® hepatocyte cultures was measured
using the MTS assay (CellTiter 96® AQueous Non-Radioac-
tive Cell kit), according to the supplier’s protocol. Briefly,
the stock MTS solution was thawed and diluted in Krebs
Henseleit buffer (fivefold dilution) and a volume of 0.2 mL
MTS was added per well. The cultures were incubated with
MTS for 1 h in a humidified incubator at 37°C, under an
atmosphere of 5% CO2/95% air. The absorbance was read at
490 nm against a background absorbance of 620 nm.
After the MTS incubation, the cultures were washed
twice with PBS and the proteins dissolved in 0.2 mL lysis
buffer (8.76 mg/mL NaCl; 0.2 mg MgCl2.6H2O; 1% (v/v)
NP40; 50 mmol/L Tris-HCl). The protein content was
measured using the Pierce assay.
Calculation and curve fitting
Experiments were carried out in duplicate and each
compound was tested in at least two different experi-
ments. All curve fitting was carried out using Prism
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Version 8.0 software (GraphPad Software, Inc., La Jolla,
CA, USA). Dose–response curves for test compounds
from calibration induction inductions assays were gener-
ated and the Indmax and Ind50 values were determined
by fitting the data to a three-parameter sigmoid (Hill)
equation (as described by Ripp et al. 2006). Indmax is
the maximum fold induction of CYP activity induced
by the compound and Ind50 is the concentration at
which 50% maximal induction was achieved. The Rela-
tive Induction Score (RIS) was determined using the
following equation:
RIS ¼ Cmax;u  Indmax
Cmax;u þ Ind50 (1)
The Cmax,u value for omeprazole was taken from
Mostafavi et al., Mostafavi and Tavakoli (2004); the
Cmax,u value for all other compounds used for RIS
determinations were taken from Ripp et al. (2006) or
Fahmi et al. (2008) (values for quinidine and flumazenil
were not needed as they were the negative control
compounds).
The relative induction of CYP3A4 and CYP2B6 by dif-
ferent compounds compared to the positive control was
calculated using equation 2:
%Relative PC induction ¼ Ind50;TC  1
Ind50;PC  1 ; (2)
where Ind50,TC is the Ind50 of the test compound and
Ind50,PC is the Ind50 of the positive control (rifampicin
for CYP3A4 and phenobarbital for CYP2B6.
Experiments conducted in Lab 2
The following methods were carried out in Lab 2, that is,
Sanofi, Montpellier, France.
Culture of primary human hepatocytes for
clearance assays
Cryopreserved human hepatocytes were seeded in 48-well
collagen-coated plastic plates in a chemically defined
medium adapted from Georgoff et al. (1984), consisting
in a 50/50 (v/v) mixture of Ham F12/Williams E medium
supplemented with 10% decomplemented fetal calf serum,
10 mg/L insulin, 0.8 mg/L glucagon, and antibiotics
(100 IU penicillin and 100 lg/mL streptomycin). After a
4–6 h attachment period, plating medium was removed
and replaced by the same serum-free culture medium
supplemented with HEPES (3.6 g/L), ethanolamine
(4 mg/L), transferrin (10 mg/L), linoleic acid-albumin
(1.4 mg/L), glucose (252 mg/L), sodium pyruvate
(44 mg/L), ascorbic acid (50 mg/L), arginine (104 mg/L),
and L-glutamine (0.7 g/L).
Experiments were performed in 48-well plastic plates
coated with rat tail collagen type I. Plates were seeded with
0.16 9 105 upcyte® hepatocytes per well in a final volume
of 0.2 mL. After a 3 h attachment period, the medium was
renewed with 0.1 mL serum-free medium supplemented
with HEPES (3.6 g/L), ethanolamine (4 mg/L), transferrin
(10 mg/L), linoleic acid-albumin (1.4 mg/L), glucose
(252 mg/L), sodium pyruvate (44 mg/L), ascorbic acid
(50 mg/L), arginine (104 mg/L), and L-glutamine (0.7
g/L). The following day, human hepatocytes were incu-
bated with FDA-recommended metabolic CYP probe sub-
strates at a starting concentration of 5 lmol/L for
midazolam, phenacetin, and tolbutamide, 20 lmol/L for
dextromethorphan, and 100 lmol/L for bupropion, in
0.1 mL of 0.1% BSA (v/v), containing incubation medium.
Regardless of the final concentration investigated, the final
solvent (DMSO) concentration never exceeded 0.2% (v/v).
To determine the metabolism of the different substrate
probes, kinetic studies were performed over 0–24 h. For
each time point (0, 1, 2, 3, 4, 6, 8, and 24 h), 0.7 mL ace-
tonitrile was added to the specific well for protein precip-
itation, and both extracellular medium and cell
compartment were harvested and pooled. Cell extracts
were transferred to a glass tube and stored at 20°C until
analysis by LC/MS-MS. Before analysis, cell homogenates
were sonicated for a 2–3 sec, homogenized and centri-
fuged at 6000xg for 10 min. Supernatant fluids were
then analyzed for the different probe substrates and their
specific metabolites.
Shipment and subsequent testing of upcyte®
hepatocytes cultures
Upcyte® hepatocytes which were shipped to Lab 2 were
seeded in HGM at 75,000 cells per well in a 48-well colla-
gen (type I)-coated plate on a Friday and grown for
3 days without a change in medium. On day 3 (Monday),
the medium was replaced with fresh HPM containing
0.1% DMSO, 100 lg/mL streptomycin and 100 U/mL
penicillin; the plates were then sealed and shipped to Lab
2 by overnight courier. Upon arrival, the medium was
replaced with HPM containing 0.1% DMSO, 100 lg/mL
streptomycin, and 100 U/mL penicillin and allowed to
recover overnight.
Upcyte® hepatocyte clearance and inhibition
assays
After shipping and the recovery period, upcyte® hepato-
cytes were cultured in HPM containing 0.1% DMSO,
100 lg/mL streptomycin, and 100 U/mL penicillin for a
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further 2 days before incubation with test compounds.
The clearance and inhibition studies were conducted
using the same conditions as those for primary human
hepatocytes (described above). The effect of inhibitors on
the clearance of substrates was determined by incubating
them in the presence or absence of specific CYP inhibi-
tors (3 lmol/L quinidine for CYP2D6 and 3 lmol/L
ketoconazole for CYP3A) or the nonspecific mechanism-
based CYP inhibitor, 1-aminobenzotriazole (ABT (Emoto
et al. 2005)), 1 mmol/L).
Metabolite analysis by HPLC
Supernatants were analyzed for unchanged drug and
specific metabolites by LC/MS-MS: phenacetin and 4-
acetamidophenol for CYP1A2, tolbutamide and 4-
hydroxy-tolbutamide for CYP2C9, bupropion and
hydroxyl-bupropion for CYP2B6, dextromethorphan, dex-
trorphan and dextrorphan glucuronide for CYP2D6,
Midazolam, 10-hydroxymidazolam and 10-hydroxymidazo-
lam glucuronide for CYP3A activity. The data were col-
lected and processed using MassLynx 4.1 Software from
Waters-Micromass. The chromatograph (Acquity UPLC
system I Class) was fitted with an Acquity UPLC BEH
C18 column (2.1 mm i.d. 9100 mm length, 1.7 lm par-
ticle size), coupled to a Xevo TQS mass spectrometer (all
from Waters, Milford, MA) and used in electrospray ion
positive mode except for tolbutamide and its hydroxyl
metabolite which were analyzed in ion negative mode.
The mobile phase was a mixture of 1.5 g/L ammonium
acetate–2 mL/L formic acid (solvent A) and acetonitrile
80%–methanol 20%–0.15 g/L ammonium acetate-formic
acid 2 mL/L (solvent B). The solvent programmer was set
to deliver a flow rate of 0.35 mL/min. Compounds were
eluted in 2 min with a linear gradient from 10 to 100%
solvent B over 1 min, followed by an isocratic step at
100% for 0.7 additional minute.
Statistical evaluations
Data were evaluated for statistical differences using the
t-test in Prism Software version 6.03. A statistical differ-
ence was considered when P < 0.05.
Results
Culture optimization
We investigated whether the culture conditions could be
modified to result in cultures with higher CYP activities
than were present using standard conditions, that is, seed-
ing at 50% confluence with a 3-day preculture period
(allowing for 1 PD) in HGM followed by a 3 day culture at
confluence in HPM with daily refreshment of medium. The
main aspects investigated were the length of the preculture
period (as previous studies using these cells in the in vitro
micronucleus assay showed that there was less DNA dam-
age to the cells when they were precultured for 7 days prior
to performing the assay (N€orenberg et al. 2013), the type of
basal medium used for the culture of cells at confluence
(HGM vs. HPM) and supplementing the preculture (dur-
ing growth) and “conditioning” (i.e., at confluence) med-
ium with DMSO. Initial experiments using Donor 422A-03
showed little difference in CYP activities when the precul-
ture medium contained 0.25 or 0.5% DMSO (data not
shown); therefore, in order to ensure maximal CYP activi-
ties, all subsequent experiments included 0.5% DMSO in
the preculture HGM medium. The effect of DMSO on
CYP2B6 and CYP3A4 activities in upcyte® hepatocytes
from all four donors was measured using a 7-day precul-
ture followed by three daily treatments with HPM supple-
mented with a range of concentrations of DMSO (Fig. 1).
Activities of both CYPs in cells from all four donors were
markedly induced in a concentration-dependent manner
by DMSO and maximal effects were evident at 0.5–0.75%
(v/v) DMSO. At higher concentrations of DMSO, there was
a decrease in both CYP activities.
Figure 2 shows how the culture conditions affected
CYP2B6 and CYP3A4 activities in upcyte® hepatocytes
from four donors. The conditions compared were as fol-
lows: (1) standard culture conditions (allowing for 1 PD);
(2) seeding at 3% confluence (5000 cells/cm2) in a T-flask
with a 6–7-day preculture period (allowing for ~3.5 PDs)
in HGM supplemented with 0.5% DMSO followed by
trypsinization, seeding at confluence (i.e., 150,000/cm2)
and a 3 day culture in HGM with 0.5% DMSO with daily
refreshment of medium; and (3) seeding at 3% confluence
in a T-flask with a 6–7-day preculture period in HGM sup-
plemented with 0.5% DMSO followed by trypsinization,
seeding at confluence (i.e., 150,000/cm2), and a 3 day cul-
ture at confluence in HPM with 0.1% DMSO with daily
refreshment of medium. Increasing the preculture time
from 3 days to 7 day did not increase the CYP3A4 activi-
ties but in three of the four donors, CYP2B6 activity was
significantly increased. CYP3A4 activities were increased
when the conditioning medium (used when the cells were
at confluence) was changed from growth medium (HGM)
to endpoint medium (HPM) with a lower concentration of
DMSO (0.1% v/v). All further experiments were conducted
using a 6–7 preculture period using HGM supplemented
with 0.5% DMSO, trypsinization, seeding at 5000 cells/
cm2, and conditioning for 3 days with HPM supplemented
with 0.1% DMSO.
Table 1 compares the CYP activities in control incuba-
tions of upcyte® hepatocytes (using the optimized condi-
tions) and corresponding primary human hepatocyte
2015 | Vol. 3 | Iss. 5 | e00161
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cultures from which they were derived. Two laboratories
(Lab 1 and Lab 2) measured CYP activities to investigate
to determine whether the shipment of the cells from Ger-
many to France markedly affected the performance of the
cells and whether they can be used in metabolism and
inhibition assays in a second laboratory. The incubations
at Lab 2 were designed for clearance of the parent com-
pound and therefore employed lower substrate concentra-
tions than those at Lab 1 (see below). For hepatocytes
from two of the four donors (151-03 and 422A-03),
upcyte® and primary hepatocytes from the same donor
were incubated under the same conditions (at Lab 2).
As with primary hepatocytes, the CYP activities in
upcyte® hepatocytes varied between donors. CYP1A2
activities were present in upcyte® hepatocytes from all
four donors, although this activity in Donors 653-03 and
151-03 was only detected by Lab 2 (using 24 h incuba-
tions and analysis by LC-MS), and all were lower than
in corresponding paired donor hepatocytes. CYP2B6-
mediated bupropion hydroxylation was markedly higher
in upcyte® hepatocytes incubated in both laboratories
compared to that in the original primary hepatocytes
(either measured by the supplier (all donors) or, in Lab
2, incubated under the same conditions as upcyte®
hepatocytes (Donor 422A-03)). CYP2C9 activities in
upcyte® hepatocytes were higher in cells cultured and
incubated at Lab 1 than those shipped and incubated at
Lab 2. This could have been due to a number of factors,
including the substrate concentration (75 lmol/L at Lab
1 and 5 lmol/L at Lab 2), the effect of shipment, and/
or the small difference in the preculture methods (which
was shorter for Lab 2 studies (see Materials and Meth-
ods)). CYP2C9 activities derived from incubations with a
high tolbutamide concentration (75 lmol/L, Lab 1), were
higher in upcyte® hepatocytes from Donor 10-03 than
the paired primary cells (also incubated at 75 lmol/L,
Provider). In Lab 2, in which upcyte® and primary
hepatocytes from Donors 151-03 and 442A-03 were
incubated under the same conditions – at a low tolbuta-
mide concentration (5 lmol/L) – CYP2C9 activities were
similar. CYP3A4 activities, measured using testosterone
and midazolam, were markedly higher in upcyte®
hepatocytes than in their paired primary cells. Notably,
phase 2 conjugation of 10-hydroxymidazolam to its glu-
curonide was also detected in upcyte® hepatocytes, the
rate of which was comparable to that in primary cells.
Dextromethorphan is metabolized by CYP3A4 to
3-methoxymorphinan (Yu and Haining 2001) and,
although no comparative data were available, the pres-
ence of this pathway was clearly evident in upcyte®
hepatocytes. CYP2D6 activities were low in the original
primary hepatocytes (2–4 pmol/min/mg, compared to an
average of ~20 pmol/min/mg in primary cells (www.bio
reclamationivt.com, accessed 20 April 2014); therefore,
activities in upcyte® and primary hepatocyte were con-
sidered to be equivalent. The CYP2D6 metabolite, dextr-
orphan, was further metabolized to its glucuronide in
both upcyte® and primary hepatocytes.
Inhibition studies
Inhibition studies were conducted in two laboratories, one
using short-term incubation period of 1 h and higher sub-
strate concentrations (Lab 1) and the second incubated at
time points over 24 h at substrate concentrations at or
below Km (Lab 2). Although the CYP1A2 activities that
were present in upcyte® hepatocytes were measurable, cells
incubated in Lab 1 were preinduced with 100 lmol/L
omeprazole in order to obtain consistently high CYP1A2
activities for the inhibition studies using UV-HPLC as the
analytical method. Two preinduction regimen were investi-
gated, namely a single treatment of 100 lmol/L omepra-
(A)
(B)
Figure 1. Effect of DMSO on CYP3A4 (A) and CYP2B6 (B) activities
in upcyte hepatocytes from different donors. Donor 10-03 = ○;
Donor 151-03 = ●; Donor 422A-03 = ▲; Donor 653-03 = □. Values
are a mean of two experiments, each with n = 2 wells per treatment.
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zole over 3 days and a daily treatment of 100 lmol/L
omeprazole over the same period. Both induction regimen
resulted in high CYP1A2 activities in upcyte® hepatocytes
from Donors 422A-03 and 10-03 (>40 pmol/min/mg pro-
tein), suggesting both could be employed for CYP1A2 inhi-
bition studies. In our studies, we used daily treatments as
this resulted in higher CYP1A2 activities than a single treat-
ment. The induced activities were 57.1  17.1,
83.8  21.7, 205.0  44.9, and 115.2  30.2 pmol/min/
mg protein in upcyte® hepatocytes from Donors 10-03,
151-03, 422A-03, and 653-03, respectively. CYP2B6,
CYP2C9, and CYP3A4 did not require preinduction with
an inducer; therefore, conditioning medium included
100 lmol/L omeprazole for CYP1A2 assays only.
The results for inhibition studies using upcyte® hepato-
cytes from Donor 422A-03 and conducted at Lab 1 are
shown in Figure 3 (results for Donors 10-03, 151-03, and
653-03 are shown in Fig. S1). In these studies, CYPs were
inhibited using competitive (a-naphthoflavone, miconaz-
ole, and ketoconazole) and time-dependent (ticlopidine)
inhibitors. There was a concentration-dependent inhibi-
tion of CYP1A2, CYP2B6, CYP2C9, and CYP3A4, such
that at the highest concentration all activities were com-
pletely inhibited. The inhibitors did not cause significant
cytotoxicity at any concentration tested in upcyte® he-
patocytes from all four donors (with the exception of tic-
lopidine, which caused ~10% cytotoxicity in upcyte®
hepatocytes from Donor 151-03 at the highest concentra-
tion only). The inhibition of different CYPs was repro-
ducible across experiments (Fig. 3 and Fig. S1) and in
upcyte® hepatocytes from all four donors tested
(Table 2). The IC50 values for each CYP tested also com-
pared well with those reported in primary human hepato-
cytes or human liver microsomes (Table 2), such that all
four CYP inhibitors were classified as potent inhibitors of
the respective CYP.
Results for inhibition studies using upcyte® hepato-
cytes from three donors and conducted at Lab 2 are
shown in Table 3. In these studies, cultures were coincu-
bated over 24 h with either the nonspecific mechanism-
based CYP inhibitor, ABT, or the CYP-selective inhibi-
tors (ketoconazole for CYP3A4 and quinidine for
CYP2D6). ABT was a potent inhibitor of all CYPs tested
and inhibited between 90% and 100% of activities over
6 h and 24 h. Ketoconazole also inhibited midazolam
metabolism by ~90% over 6 h but this effect was lower
after 24 h (between 40% and 75%), most likely due to
the metabolism of the inhibitor over this time period.
CYP2D6-selective inhibition by quinidine was low and
did not reach more than 47% inhibition. As with
CYP3A4 inhibition by ketoconazole, the inhibitory effect
of quinidine on CYP2D6 was lower after 24 h, both
observations (low % inhibition and time-dependent
effects) possibly due to the metabolism of quinidine.
The production of the CYP3A4-mediated metabolite of
dextromethorphan, 3-methoxymorphinan, was almost
(A) (B)
(C) (D)
Figure 2. Effect of preculture time and DMSO treatment on CYP2B6 and CYP3A4 activities in upcyte hepatocytes from different donors. White
bars represent cells grown over a 3 day preculture and 3 days conditioning at confluence in GM +0.1% DMSO (standard conditions); gray bars
represent cells grown over a 6–7-day preculture period followed by reseeding at confluence and a 3 day conditioning in HGM +0.5% DMSO, and
black bars represent cells grown over a 6–7-day preculture period followed by reseeding at confluence and a 3 day conditioning in HPM +0.1%
DMSO. Values are a mean of two experiments, each with n = 3 wells per treatment. *Significantly different from standard conditions (P < 0.05).
DMSO, dimethyl sulfoxide, HGM, hepatocyte growth medium, HPM, high-performance medium.
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completely inhibited by ABT but, in contrast, quinidine
either had little or no inhibitory effect on this pathway,
confirming the CYP-selective properties of this inhibitor.
Interestingly, in the case of Donor 653-03, quinidine
marginally increased the production of the metabolite at
both time points, possibly as a result of the diversion of
the metabolic pathways towards CYP3A4 as the clearance
of the parent compound did not change (data not
shown).
These results support the use of upcyte® hepatocytes in
inhibition studies incubated in short-term assays to derive
an IC50 value, or in longer term assays to determine clear-
ance in the presence and absence of selected inhibitors.
CYP induction
Induction of CYP1A2, CYP2B6, CYP2C9, and
CYP3A4 in upcyte® hepatocytes
Upcyte® hepatocytes from all four donors tested using a
3 day preculture period were responsive to CYP1A2,
CYP2B6, CYP2C9, and CYP3A4 induction by prototypical
(A) (B)
(C) (D)
Figure 3. Inhibition of (A) CYP1A2 by a–naphthoflavone, (B) CYP2B6 by ticlopidine, (C) CYP2C9 by miconazole, and (D) CYP3A4 by
ketoconazole in upcyte hepatocytes from Donor 422A-03. Values are the mean  SD from triplicates in 2–5 experiments (denoted by different
symbols).
Table 2. IC50 values of CYP inhibitors incubated with upcyte
 hepatocytes from different donors. For comparison, literature values for












upcyte Primary1 upcyte Microsomes2 upcyte Primary3 upcyte Primary3
10-03 0.15, 0.04 (n = 2) 0.1 8.1  1.6 (n = 4) 0.32 251, 95.8 (n = 2) 2.12 0.30  0.3 (n = 4) 0.28
0.14151-03 0.38, 0.19 (n = 2) 36.1  27.9 (n = 4) 12, 6.6 (n = 2) 0.15  0.01 (n = 4)
422A-03 0.46  0.22 (n = 4) 7.3  1.6 (n = 4) 3.1, 4.3 (n = 2) 0.27  0.06 (n = 5)
653-03 0.36, 0.12 (n = 2) 27.5  19.7 (n = 4) 14.7, 4.1 (n = 2) 0.23  0.12 (n = 4)
1Moeller et al. (2013).
2Turpeinen et al. (2004) (microsomes).
3Mao et al. (2012) and Moeller et al. (2013).
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inducers (Fig. 4). The only exception was CYP2C9 induc-
tion in upcyte® hepatocytes from Donor 653-03, in which
this activities was already relatively high (51 pmol/min/
mg). The responsiveness to CYP inducers was a signifi-
cant finding as induction of CYP2B6 in first-generation
upcyte® hepatocytes only evident at the mRNA level
(Burkard et al. 2012). This suggests the responsiveness of
these cells, especially via CAR, was improved by the
refined process used to produce second-generation up-
cyte® hepatocytes. Likewise, upcyte® hepatocytes demon-
strated functional AhR- and PXR-mediated CYP
induction as CYP1A2 and CYP3A4 were also induced by
omeprazole and rifampicin, respectively.
In order to rule out false positive results from CYP3A4
induction studies, the FDA recommends including a nega-
tive control, that is, a noninducer, in each induction assay.
In these assays, two negative controls were included,
namely quinidine (0.1–250 lmol/L) and flumazenil (0.05–
50 lmol/L), both of which did not induce CYP3A4 or
CYP2B6 at any concentration tested (data not shown).
Prediction models for in vivo CYP3A4 induction
There are three main prediction models recommended by
the FDA, EMA, and PhARMA for CYP3A4 induction
(Chu et al. 2009; EMA, 2012; FDA, 2012), namely, the
RIS, AUCu/F2, and Cmax,u/Ind50. Data from upcyte
® he-
patocytes from Donor 653 were used to compare the dif-
ferent models (Fig. 5). Of the three, the fit was best when
the RIS (R2 = 0.92) and Cmax,u/Ind50 (R
2 = 0.93) were
used; however, the F2 value (R
2 = 0.89) may also be used
when compounds are too toxic or insoluble to reach a
maximal induction response. The Indmax and Ind50 values
from all four donors were applied to the RIS model
(values shown in Table 4) and, although the calibration
curves were different across donors, they all exhibited a
good fit of the data (R2 = 0.87–0.94, Figs. 5C, 6).
CAR and PXR selective induction of CYP3A4 and
CYP2B6 in upcyte® hepatocytes
The relative induction of CYP2B6 and CYP3A4 is known
to be a result of selective activation of either the PXR or
CAR receptors (Faucette et al. 2007); therefore, we inves-
tigated this attribute by treating upcyte® hepatocytes with
different inducers and measuring CYP3A4 and CYP2B6
activities in the same wells. Table 5 summarizes the
CYP3A4 and CYP2B6 induction responses of upcyte® he-
patocytes from all donors to the same compounds tested
for CYP3A4 induction. Figure 7 compares the relative
induction of both CYPs (compared to the maximal fold
induction by the positive controls, according to
equation 2 in the Materials and Methods) by the PXR
Table 3. Inhibition of CYP activities in upcyte hepatocytes from different donors incubated in Lab 2.
CYP Metabolite(s) Inhibitor
Donor 151-03 Donor 422A-03 Donor 653-03
0–6 h 24 h 0–6 h 24 h 0–6 h 24 h
1A2 APAP 1 mmol/L ABT 100 100 100 98 95 96
2B6 OH-Bup 1 mmol/L ABT 85 94 90 94 94 97
2C9 OH-Tolb 1 mmol/L ABT 100 98 100 100 95 99
3A4 10OH-MID 1 mmol/L ABT 99 97 98 98 98 98
+10OH-MID-G 3 lmol/L ketoconazole 91 40 93 75 87 58
3A4 MEM 1 mmol/L ABT 94 96 92 95 91 97
3 lmol/L Quinidine 0 0 10 10 38 38
2D6 Dex+Dex-G 1 mmol/L ABT 100 91 100 92 100 91
3 lmol/L Quinidine 47 15 24 16 36 21
Values are expressed as a percentage inhibition (including phase 1 and 2 metabolites). “38%” denotes the activity was increased by 38% in the
presence of the inhibitor.
(A) (B)
(C) (D)
Figure 4. Induction of (A) CYP1A2 (by 50 lmol/L omeprazole), (B)
CYP2B6 (by 2 mmol/L phenobarbital), (C) CYP2C9 (by 20 lmol/L
rifampicin), and (D) CYP3A4 (by 20 lmol/L rifampicin) in upcyte
hepatocytes from Donors 10-03, 151-03, 422A–03, and 653-03.
White bars indicate control values and black bars indicate values for
the prototypical inducers. Values are the mean  SD from triplicates.
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selective drug, rifampicin, the CAR-selective drugs, phe-
nytoin and carbamazepine; and the mixed activator, phe-
nobarbital in all four donors. The relative induction of
CYP3A4 and CYP2B6 was compound-specific and donor-
dependent. Rifampicin was a potent inducer of CYP3A4
in all upcyte® hepatocytes (Table 5), and only phenobar-
bital and phenytoin caused a higher induction (137% and
120% of rifampicin maximal induction in Donor 422A-03
and Donor 653-03, respectively (Fig. 7C, D, gray bars).
Rifampicin was also a strong inducer of CYP2B6 in up-
cyte® hepatocytes from Donor 422A-03 (108% of the
maximal PB response, Fig. 7C). In contrast, rifampicin




Figure 5. Comparison of calibration curves for (A) RIS, (B) AUCu/F2,
and (C) Cmax,u/Ind50 using upcyte
 hepatocytes from Donor 653.
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hepatocytes from Donors 10-03, 151-03, and 653-03
(between 14% and 34% of the maximal PB response).
Phenobarbital was a strong inducer of both CYP3A4 and
CYP2B6 and resulted in maximal induction of both CYPs
in upcyte® hepatocytes from all four donors. Phenytoin
was also a strong inducer of CYP3A4, in keeping with the
findings of Raucy (Raucy 2003) who showed that phenyt-
oin increased CYP3A4 mRNA markedly and the response
was equivalent to that seen with rifampicin. Phenytoin is
a weak PXR activator (Raucy 2003) and was subsequently
shown to be a selective activator of CAR (Wang et al.
2004). This was reflected in these studies by the predomi-
nance for CYP2B6 over CYP3A4 induction by this
compound in three of the four donors (e.g., the induction
of CYP2B6 and CYP3A4 in upcyte® hepatocytes from
Donor 151-03 was 130% and 60% of the positive con-
trols, respectively). Although carbamazepine was a moder-
ate inducer of CY3A4 and CYP2B6, the relative
predominance for CYP2B6 induction was also evident for
this CAR-selective compound in three of the four
Donors.
Discussion
We have investigated the applicability of second-generation
upcyte® hepatocytes to metabolism-related assays. In order
to carry out these assays, the cells should express sufficient
levels of CYP activities; therefore, our initial studies
explored whether the inclusion of DMSO in the media
could increase CYP activities. DMSO is known to induce
CYP3A4 activities in primary human hepatocytes (LeC-
luyse 2001) and CYP3A4 and CYP2B6 activities in HepaRG
cells (Antherieu et al. 2010) by activating PXR and/or
CAR, although, CYP1A2 is not induced over the same con-
centration of DMSO (LeCluyse 2001). Our investigations
confirmed that supplementing the medium with DMSO
could be beneficial to the overall XME properties of the
cells. During the preculture, HGM can be supplemented
with 0.5% DMSO but during the conditioning period,
HPM and not HGM should be used as the basal medium
and optimally supplemented with 0.1% DMSO. The reason
for lower XME activities cells conditioned in DMSO-sup-
plemented HGM may be due to a downregulation of CYPs
when the DMSO concentration is maintained at the higher
concentration and/or that factors in the growth medium
may not be suitable for differentiating the cells once they
reach confluence. The concentration of 0.1% DMSO in the
conditioning medium was considered acceptable as it is the
standard solvent and concentration for many test com-
pound control incubations.
The metabolism studies conducted in two laboratories
demonstrated that second-generation upcyte® hepatocytes
maintained in optimized culture conditions expressed
good levels of CYP activities equivalent to or higher than
those in paired primary cell cultures from the same
donor. With the exception of CYP1A2, the CYP activities
were generally higher than in their corresponding primary
human hepatocyte cultures. Despite the low CYP1A2
activities demonstrated in short-term incubations of 1 h,
longer incubations of 24 h showed that CYP1A2 sub-
strates were also metabolized. Moreover, in the case of
CYP2B6 and CYP3A4, activities in upcyte® hepatocytes
were 5- to 10-fold higher then paired primary cultures.
Although different substrate concentrations were used,
the relative levels of activities measured in upcyte®




Figure 6. Comparison of calibration curves for RIS from three donors
of upcyte hepatocytes (Donor 10-03 (A); Donor 151-03 (B) and
Donor 422A-03 (C)). Values are the mean from duplicate values of
two experiments. RIS, relative induction score.
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two laboratories, confirming that shipment of live cells
does not markedly compromise the cells. The good levels
of CYP activities in these cells makes them a promising
model for long-term (>24 h) incubations for generating
and identifying metabolites, as well as clearance and inhi-
bition studies, which all require XMEs higher than that
present in short-term cultures of primary human hepato-
cytes. Upcyte® hepatocytes therefore offer an advantage
over liver microsomes and hepatocytes, which generally
do not metabolize test compounds sufficiently in short-
term assays (<24 h) to determine an area under the curve
measurement (Di et al. 2012). The studies carried out in
Lab 2 also support the use of upcyte® hepatocytes in
clearance assays for stable compounds, as these were con-
ducted over 24 h and demonstrated good metabolic func-
tion over the entire incubation period. In additional to
metabolism studies, we have shown that second-genera-
tion upcyte® hepatocytes can also be used in CYP
inhibition studies, which also require sufficient metabolic
activities to ensure a good dynamic range. For CYP1A2,
inhibition assays can be conducted using a 24 h incuba-
tion period to ensure higher control activities; whereas,
incubations of 1 h require boosting of CYP activity by
preinducing CYP1A2 (e.g., with omeprazole). All four
CYPs were inhibited in a concentration-dependent man-
ner and the calculated IC50 values confirmed that all ref-
erence compounds tested were potent inhibitors of the
respective CYPs.
Second-generation upcyte® hepatocytes were responsive
to prototypical CYP1A2, CYP2B6, CYP2C9, and CYP3A4
inducers, confirming that they have functional AhR-, CAR-
, and PXR-mediated CYP regulation. Additional studies
carried out at Lab 2 investigated the effect of prototypical
inducers (omeprazole, phenobarbital, and rifampicin) on a
panel of CYP, UDP-glucuronosyltransferase (UGT), and
transporter mRNAs and showed that the induction pattern
was similar to that in human hepatocytes (data not shown).
These findings support the use of second-generation
upcyte® hepatocytes for investigating the induction of
multiple genes using mRNA as the endpoint measurement.
Like primary human hepatocytes, there were differences in
the responsiveness of upcyte® hepatocytes to CYP inducers.
There were also differences in the CYP3A4 and CYP2B6
induction responses in the same cultures of upcyte® he-
patocytes to different inducers. For example, phenytoin
preferentially activates CAR over PXR, evident in these cells
as a more potent induction of CYP2B6 than CYP3A4 at the
same concentration. By contrast, rifampicin was a more
potent inducer of CYP3A4 than phenytoin, indicative of
the preferential activation of PXR by this potent inducer.
The CAR and PXR selective induction of CYP3A4 and
CYP2B6 in upcyte® hepatocyte correspond to the findings
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barbital, and rifampicin to be classified as strong inducers,
and carbamazepine as a moderate inducer of CYP2B6
(based on mean fold induction values). By contrast, dexa-
methasone – a known PXR selective activator – did not
induce CYP2B6 in upcyte® hepatocytes from any of the
donors but it was a weak inducer of CYP3A4 (Table 5).
Troglitazone is a mixed PXR/CAR activator and induced
both CYP3A4 and CYP2B6. This drug is known to cause
in vivo CYP3A4 induction; whereas, pioglitazone is a weak
inducer (Sahi et al. 2003; Ripp et al. 2006). In upcyte® he-
patocytes, troglitazone was a more potent inducer of both
CYP3A4 and CYP2B6 than pioglitazone, either due to a
higher fold induction or a lower Ind50 (i.e., the efficiency
ratio was higher).
There was a good fit of data from these studies when
they were applied to three different predictive models for
CYP3A4 induction, namely the RIS, AUCu/F2, and
Cmax,u/Ind50. Importantly, there was a very good intra- and
interexperimental reproducibility of the measurements for
all end points measured in these studies. Induction studies
on one donor of first-generation upcyte® hepatocytes
showed that the Indmax and Ind50 values, and consequently
the RIS values, were similar at each growth stage (spanning
15 PDs) (Burkard et al. 2012). Additional investigations on
second-generation upcyte® hepatocytes showed that the
fold induction of CYP3A4 by rifampicin was also consistent
at different stages of growth (between a PD of 21 and 42
(Levy et al. 2015)). Therefore, as the PD of all the cells used
in these studies was between 20 and 25, we did not expect
marked variation in the results between batches from the
same donor. For researchers employing the RIS calibration
curve as part of their screening process, the robust nature
of these cells means that the calibration curve would not
need to be repeated once established (although a yearly
check would be advisable). By contrast, those who employ
cryopreserved human hepatocytes for the same assay need
to re-establish a new calibration curve for each batch once
the previous batch is depleted. Since billions of upcyte® he-
patocytes from a number of donors are available results
over a period of years can be compared.
In conclusion, second-generation upcyte® hepatocytes
are a promising model with which to test the metabolism
and drug interaction potential of novel compounds prior
to being tested in regulatory submission studies using pri-
mary human hepatocytes. Upcyte® hepatocytes represent a
more predictive and relevant tool for predicting enzyme
induction than PXR activation studies or receptor-binding
assays. A genome-wide comparison between these cells
and primary hepatocytes and/or human liver tissue would
be necessary to confirm their use as a surrogate for pri-
mary hepatocytes. Under the culture conditions used,
these cells expressed good amounts of CYP activities,
which could be inhibited by CYP-selective inhibitors.
Upcyte® hepatocytes are responsive to CYP1A2, CYP2B6,
CYP2C9, and CYP3A4 induction and can be used to pre-
dict in vivo CYP3A4 induction potential using three com-
mon prediction models. The availability of large quantities
of cells from multiple donors makes upcyte® hepatocytes
(A) (B)
(C) (D)
Figure 7. A comparison of % maximum fold induction by rifampicin, phenobarbital, phenytoin, and carbamazepine in upcyte hepatocytes from
different donors (Donor 10-03 (A); Donor 151-03 (B); Donor 422A-03 (C); Donor 653-03 (D)). Black bars indicate values for CYP3A4 and white
bars indicate values for CYP2B6. Values are the mean from duplicate values of 2 experiments.
ª 2015 Upcyte Technologies GmbH. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
2015 | Vol. 3 | Iss. 5 | e00161
Page 15
S. D. Ramachandran et al. CYP Induction and Inhibition Assays Using Upcyte® Hepatocytes
suitable for drug–drug interaction (DDI) screening, as well
as more in-depth mechanistic investigations.
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